Base de dados : MEDLINE
Pesquisa : D04.345.566.780.110 [Categoria DeCS]
Referências encontradas : 2781 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 279 ir para página                         

  1 / 2781 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28457834
[Au] Autor:Jorge P; Pérez-Pérez M; Pérez Rodríguez G; Pereira MO; Lourenço A
[Ad] Endereço:Centre of Biological Engineering (CEB), Laboratory of Research in Biofilms Rosário Oliveira (LIBRO), University of Minho, Campus de Gualtar, Braga 4710-057, Portugal.
[Ti] Título:A network perspective on antimicrobial peptide combination therapies: the potential of colistin, polymyxin B and nisin.
[So] Source:Int J Antimicrob Agents;49(6):668-676, 2017 Jun.
[Is] ISSN:1872-7913
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Antimicrobial combinations involving antimicrobial peptides (AMPs) attract considerable attention within current antimicrobial and anti-resistance research. The objective of this study was to review the available scientific literature on the effects of antimicrobial combinations involving colistin (polymyxin E), polymyxin B and nisin, which are US Food and Drug Administration (FDA)-approved AMPs broadly tested against prominent multidrug-resistant pathogens. A bioinformatics approach based on literature mining and manual expert curation supported the reconstruction of experimental evidence on the potential of these AMP combinations, as described in the literature. Network analysis enabled further characterisation of the retrieved antimicrobial agents, targets and combinatory effects. This systematic analysis was able to output valuable information on the studies conducted on colistin, polymyxin B and nisin combinations. The reconstructed networks enable the traversal and browsing of a large number of agent combinations, providing comprehensive details on the organisms, modes of growth and methodologies used in the studies. Therefore, network analysis enables a bird's-eye view of current research trends as well as in-depth analysis of specific drugs, organisms and combinatory effects, according to particular user interests. The reconstructed knowledge networks are publicly accessible at http://sing-group.org/antimicrobialCombination/. Hopefully, this resource will help researchers to look into antimicrobial combinations more easily and systematically. User-customised queries may help identify missing and less studied links and to generate new research hypotheses.
[Mh] Termos MeSH primário: Antibacterianos/uso terapêutico
Colistina/uso terapêutico
Quimioterapia Combinada/métodos
Nisina/uso terapêutico
Polimixina B/uso terapêutico
[Mh] Termos MeSH secundário: Animais
Pesquisa Biomédica/métodos
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 1404-26-8 (Polymyxin B); 1414-45-5 (Nisin); Z67X93HJG1 (Colistin)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170502
[St] Status:MEDLINE


  2 / 2781 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29040287
[Au] Autor:Betts J; Nagel C; Schatzschneider U; Poole R; La Ragione RM
[Ad] Endereço:Department of Pathology and Infectious Disease, School of Veterinary Medicine, University of Surrey, Guildford, United Kingdom.
[Ti] Título:Antimicrobial activity of carbon monoxide-releasing molecule [Mn(CO)3(tpa-κ3N)]Br versus multidrug-resistant isolates of Avian Pathogenic Escherichia coli and its synergy with colistin.
[So] Source:PLoS One;12(10):e0186359, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Antimicrobial resistance is a growing global concern in human and veterinary medicine, with an ever-increasing void in the arsenal of clinicians. Novel classes of compounds including carbon monoxoide-releasing molecules (CORMs), for example the light-activated metal complex [Mn(CO)3(tpa-κ3N)]Br, could be used as alternatives/to supplement traditional antibacterials. Avian pathogenic Escherichia coli (APEC) represent a large reservoir of antibiotic resistance and can cause serious clinical disease in poultry, with potential as zoonotic pathogens, due to shared serotypes and virulence factors with human pathogenic E. coli. The in vitro activity of [Mn(CO)3(tpa-κ3N)]Br against multidrug-resistant APECs was assessed via broth microtitre dilution assays and synergy testing with colistin performed using checkerboard and time-kill assays. In vivo antibacterial activity of [Mn(CO)3(tpa-κ3N)]Br alone and in combination with colistin was determined using the Galleria mellonella wax moth larvae model. Animals were monitored for life/death, melanisation and bacterial numbers enumerated from larval haemolymph. In vitro testing produced relatively high [Mn(CO)3(tpa-κ3N)]Br minimum inhibitory concentrations (MICs) of 1024 mg/L. However, its activity was significantly increased with the addition of colistin, bringing MICs down to ≤32 mg/L. This synergy was confirmed in time-kill assays. In vivo assays showed that the combination of [Mn(CO)3(tpa-κ3N)]Br with colistin produced superior bacterial killing and significantly increased larval survival. In both in vitro and in vivo assays light activation was not required for antibacterial activity. This data supports further evaluation of [Mn(CO)3(tpa-κ3N)]Br as a potential agent for treatment of systemic infections in humans and animals, when used with permeabilising agents such as colistin.
[Mh] Termos MeSH primário: Colistina/administração & dosagem
Sinergismo Farmacológico
Escherichia coli/efeitos dos fármacos
Compostos Organometálicos/administração & dosagem
[Mh] Termos MeSH secundário: Animais
Anti-Infecciosos/administração & dosagem
Aves/microbiologia
Resistência a Múltiplos Medicamentos/efeitos dos fármacos
Escherichia coli/patogenicidade
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Infective Agents); 0 (Organometallic Compounds); Z67X93HJG1 (Colistin)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171031
[Lr] Data última revisão:
171031
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171018
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0186359


  3 / 2781 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28931235
[Au] Autor:Nielsen TB; Pantapalangkoor P; Luna BM; Bruhn KW; Yan J; Dekitani K; Hsieh S; Yeshoua B; Pascual B; Vinogradov E; Hujer KM; Domitrovic TN; Bonomo RA; Russo TA; Lesczcyniecka M; Schneider T; Spellberg B
[Ad] Endereço:Department of Medicine and Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles.
[Ti] Título:Monoclonal Antibody Protects Against Acinetobacter baumannii Infection by Enhancing Bacterial Clearance and Evading Sepsis.
[So] Source:J Infect Dis;216(4):489-501, 2017 Aug 15.
[Is] ISSN:1537-6613
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Background: Extremely drug-resistant (XDR) Acinetobacter baumannii is one of the most commonly encountered, highly resistant pathogens requiring novel therapeutic interventions. Methods: We developed C8, a monoclonal antibody (mAb), by immunizing mice with sublethal inocula of a hypervirulent XDR clinical isolate. Results: C8 targets capsular carbohydrate on the bacterial surface, enhancing opsonophagocytosis. Treating with a single dose of C8 as low as 0.5 µg/mouse (0.0167 mg/kg) markedly improved survival in lethal bacteremic sepsis and aspiration pneumonia models of XDR A. baumannii infection. C8 was also synergistic with colistin, substantially improving survival compared to monotherapy. Treatment with C8 significantly reduced blood bacterial density, cytokine production (tumor necrosis factor α, interleukin [IL] 6, IL-1ß, and IL-10), and sepsis biomarkers. Serial in vitro passaging of A. baumannii in the presence of C8 did not cause loss of mAb binding to the bacteria, but did result in emergence of less-virulent mutants that were more susceptible to macrophage uptake. Finally, we developed a highly humanized variant of C8 that retains opsonophagocytic activity in murine and human macrophages and rescued mice from lethal infection. Conclusions: We describe a promising and novel mAb as therapy for lethal, XDR A. baumannii infections, and demonstrate that it synergistically improves outcomes in combination with antibiotics.
[Mh] Termos MeSH primário: Infecções por Acinetobacter/tratamento farmacológico
Acinetobacter baumannii/efeitos dos fármacos
Anticorpos Monoclonais/farmacologia
Sepse/tratamento farmacológico
[Mh] Termos MeSH secundário: Animais
Antibacterianos/farmacologia
Biomarcadores/sangue
Colistina/farmacologia
Citocinas/sangue
Modelos Animais de Doenças
Farmacorresistência Bacteriana Múltipla
Células HL-60
Seres Humanos
Macrófagos/imunologia
Macrófagos/microbiologia
Masculino
Camundongos
Camundongos Endogâmicos C3H
Sepse/microbiologia
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Antibodies, Monoclonal); 0 (Biomarkers); 0 (Cytokines); Z67X93HJG1 (Colistin)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170928
[Lr] Data última revisão:
170928
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170922
[St] Status:MEDLINE
[do] DOI:10.1093/infdis/jix315


  4 / 2781 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28846777
[Au] Autor:Blanco AR; Nostro A; D'Angelo V; D'Arrigo M; Mazzone MG; Marino A
[Ad] Endereço:SIFI SpA, Aci S. Antonio, Catania, Italy.
[Ti] Título:Efficacy of a Fixed Combination of Tetracycline, Chloramphenicol, and Colistimethate Sodium for Treatment of Candida albicans Keratitis.
[So] Source:Invest Ophthalmol Vis Sci;58(10):4292-4298, 2017 Aug 01.
[Is] ISSN:1552-5783
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Purpose: To evaluate the antifungal activity of a fixed antibiotic combination (AC) containing tetracycline (TET), chloramphenicol (CAF), and colistimethate sodium (CS). Methods: In vitro: Candida ATCC and clinical strains were used. The minimum inhibitory concentrations (MICs) of AC and of each antibiotic were determined. Fluconazole (FLC) was tested for comparison. Time-killing curves of selected strains were performed. Ex vivo keratitis: corneas were injected intrastromally with the selected strains. After the injection, corneas were divided into groups of treatments: AC, FLC, or saline. Then, the tissues were analyzed for colony-forming units per gram (CFU/g). Propidium iodide (PI) and MitoTracker (MTR) staining were used to investigate the mode of action. Results: Values of MIC required to inhibit the growth of 90% of organisms for the antibiotics alone were higher than FLC. However, their activity was enhanced when used in combination against Candida yeasts. Time-killing curves showed that at 24 hours, AC reduced the load of both strains of approximately 1 Log10 CFU/g compared with the initial inoculum (P < 0.0001). This effect was also significant versus FLC. In ex vivo, AC was effective in decreasing the loads of both strains by 4 Log10 CFU/g with respect to the control. Moreover, it showed higher activity than FLC against Candida albicans ATCC 10231 (1 Log10 CFU/g, P < 0.01 versus control). PI staining demonstrated that CS changed the membrane's permeability, whereas MTR staining demonstrated that TET or CAF altered mitochondrial function. The cells treated with AC and stained showed both effects. Conclusions: In this study, AC showed antifungal efficacy versus Candida spp.; this activity can be due to the synergistic effects of antibiotics in it.
[Mh] Termos MeSH primário: Antibacterianos/uso terapêutico
Candida albicans/efeitos dos fármacos
Candidíase/tratamento farmacológico
Cloranfenicol/uso terapêutico
Colistina/análogos & derivados
Úlcera da Córnea/tratamento farmacológico
Infecções Oculares Fúngicas/tratamento farmacológico
Tetraciclina/uso terapêutico
[Mh] Termos MeSH secundário: Animais
Candida albicans/isolamento & purificação
Candidíase/microbiologia
Colistina/uso terapêutico
Contagem de Colônia Microbiana
Úlcera da Córnea/microbiologia
Combinação de Medicamentos
Farmacorresistência Fúngica
Sinergismo Farmacológico
Infecções Oculares Fúngicas/microbiologia
Testes de Sensibilidade Microbiana
Soluções Oftálmicas
Coelhos
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Drug Combinations); 0 (Ophthalmic Solutions); 66974FR9Q1 (Chloramphenicol); DL2R53P963 (colistinmethanesulfonic acid); F8VB5M810T (Tetracycline); Z67X93HJG1 (Colistin)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170904
[Lr] Data última revisão:
170904
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170829
[St] Status:MEDLINE
[do] DOI:10.1167/iovs.17-22047


  5 / 2781 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28842171
[Au] Autor:Lu Z; Miao Y; Muhammad I; Tian E; Hu W; Wang J; Wang B; Li R; Li J
[Ad] Endereço:College of Veterinary Medicine, Northeast Agricultural University, 59 Mucai Street, Xiangfang District, Harbin 150030, PR China; College of Life Engineering, Shenyang Institute of Technology, NO.1 (East) Binhe Road, Economic Developing District, Fushun 113122, PR China.
[Ti] Título:Colistin-induced autophagy and apoptosis involves the JNK-Bcl2-Bax signaling pathway and JNK-p53-ROS positive feedback loop in PC-12 cells.
[So] Source:Chem Biol Interact;277:62-73, 2017 Nov 01.
[Is] ISSN:1872-7786
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Ab] Resumo:Our recent study demonstrated neurotoxicity of colistin-induced autophagy and apoptosis in PC-12 cells, and that autophagy reached peak level at 12 h. In this study, we scrutinized the role of JNK in colistin-induced neurotoxicity and demonstrated the relationship among JNK, p53 and ROS in colistin treated PC-12 cells. Colistin-induced autophagy and apoptosis by JNK inhibition/activation were examined by western blotting, electron microscopy, and immunofluorescence/fluorescence microscopy. The results indicated that colistin induced JNK activation reached peak level at 12 h, while the highest levels of p-Bcl2/Bcl2 were observed at 12 h and Bax/Bcl2 significantly increased in a time-dependent manner. In PC-12 cells, inhibition of JNK by SP600125 (JNK inhibitor) resulted in significantly lower levels of autophagy upon colistin treatment, depending on the expression levels of Beclin1, LC3-II, p62 degradation and reduction in the number of autophagic vacuoles. In contrast, anisomycin pretreatment PC-12 cells led to upregulated autophagy. Especially, the highest levels of Beclin1 and p-Bcl2/Bcl2 were observed at 6 h, and Bax/Bcl2, cleaved-caspase3 and cleaved-PARP significantly increased in a time-dependent manner. The results revealed that JNK activation mediated autophagy and apoptosis related to Beclin1-Bcl2 and Bax-Bcl2 complex in colistin-treated PC-12 cells. Silencing of p53 by siRNA before colistin treatment substantially reduced ROS production and transactivated JNK in PC-12 cells. Moreover, activation of JNK increased ROS generation in PC-12 cells. In conclusion, colistin-induced autophagy and apoptosis is correlated to JNK-Bcl2-Bax signaling pathway, and an interaction effect found between intracellular ROS level and JNK-p53 signaling pathway in apoptosis.
[Mh] Termos MeSH primário: Antibacterianos/toxicidade
Apoptose/efeitos dos fármacos
Autofagia/efeitos dos fármacos
Colistina/toxicidade
Neurônios/efeitos dos fármacos
Transdução de Sinais/efeitos dos fármacos
[Mh] Termos MeSH secundário: Animais
Proteínas Quinases JNK Ativadas por Mitógeno/metabolismo
Sistema de Sinalização das MAP Quinases/efeitos dos fármacos
Neurônios/citologia
Neurônios/metabolismo
Células PC12
Proteínas Proto-Oncogênicas c-bcl-2/metabolismo
Ratos
Espécies Reativas de Oxigênio/metabolismo
Proteína Supressora de Tumor p53/metabolismo
Proteína X Associada a bcl-2/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Proto-Oncogene Proteins c-bcl-2); 0 (Reactive Oxygen Species); 0 (Tumor Suppressor Protein p53); 0 (bcl-2-Associated X Protein); EC 2.7.11.24 (JNK Mitogen-Activated Protein Kinases); Z67X93HJG1 (Colistin)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171108
[Lr] Data última revisão:
171108
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170827
[St] Status:MEDLINE


  6 / 2781 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28704517
[Au] Autor:Wang C; Zhang L; Su W; Ying Z; He J; Zhang L; Zhong X; Wang T
[Ad] Endereço:College of Animal Science and Technology, Nanjing Agricultural University, Nanjing, People's Republic of China.
[Ti] Título:Zinc oxide nanoparticles as a substitute for zinc oxide or colistin sulfate: Effects on growth, serum enzymes, zinc deposition, intestinal morphology and epithelial barrier in weaned piglets.
[So] Source:PLoS One;12(7):e0181136, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The objective of this study was to evaluate effects of zinc oxide nanoparticles (nano-ZnOs) as a substitute for colistin sulfate (CS) and/or zinc oxide (ZnO) on growth performance, serum enzymes, zinc deposition, intestinal morphology and epithelial barrier in weaned piglets. A total of 216 crossbred Duroc×(Landrace×Yorkshire) piglets weaned at 23 days were randomly assigned into 3 groups, which were fed with basal diets supplemented with 20 mg/kg CS (CS group), 20mg/kg CS+3000 mg/kg ZnO (CS+ZnO group), and 1200 mg/kg nano-ZnOs (nano-ZnO group) for 14 days. Results indicated that compared to CS group, supplementation of 1200 mg/kg nano-ZnOs (about 30 nm) significantly increased final body weight and average daily gain, and 3000 mg/kg ZnO plus colistin sulfate significantly increased average daily gain and decreased diarrhea rate in weaned piglets. There was no significant difference in growth performance and diarrhea rate between nano-ZnO and CS+ZnO groups. Supplementation of nano-ZnOs did not affect serum enzymes (glutamic oxalacetic transaminase, glutamic-pyruvic transaminase, and lactate dehydrogenase), but significantly increased plasma and tissue zinc concentrations (liver, tibia), improved intestinal morphology (increased duodenal and ileal villus length, crypt depth, and villus surface), enhanced mRNA expression of ZO-1 in ileal mucosa, and significantly decreased diamine oxidase activity in plasma, total aerobic bacterial population in MLN as compared to CS group. Effects of nano-ZnOs on serum enzymes, intestinal morphology, and mRNA expressions of tight junction were similar to those of high dietary ZnO plus colistin sulfate, while nano-ZnOs significantly reduced zinc concentrations of liver, tibia, and feces, and decreased total aerobic bacterial population in MLN as compared to CS+ZnO group. These results suggested that nano-ZnOs (1200 mg/kg) might be used as a substitute for colistin sulfate and high dietary ZnO in weaned piglets.
[Mh] Termos MeSH primário: Colistina/administração & dosagem
Diarreia/epidemiologia
Suínos/crescimento & desenvolvimento
Óxido de Zinco/administração & dosagem
[Mh] Termos MeSH secundário: Animais
Biomarcadores/análise
Peso Corporal/efeitos dos fármacos
Colistina/efeitos adversos
Diarreia/induzido quimicamente
Diarreia/veterinária
Suplementos Nutricionais
Intestinos/metabolismo
Nanopartículas/efeitos adversos
Nanopartículas/química
Distribuição Aleatória
Desmame
Óxido de Zinco/efeitos adversos
Óxido de Zinco/química
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); SOI2LOH54Z (Zinc Oxide); Z67X93HJG1 (Colistin)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170925
[Lr] Data última revisão:
170925
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170714
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0181136


  7 / 2781 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28686744
[Au] Autor:Cheng A; Chuang YC; Sun HY; Yang CJ; Chang HT; Yang JL; Sheng WH; Chen YC; Chang SC
[Ad] Endereço:Department of Internal Medicine, National Taiwan University Hospital Main Branch, and National Taiwan University College of Medicine, Taipei, Taiwan.
[Ti] Título:Should we treat patients with only one set of positive blood cultures for extensively drug-resistant Acinetobacter baumannii the same as multiple sets?
[So] Source:PLoS One;12(7):e0180967, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Acinetobacter species are not considered skin commensals and under-treatment is an overriding concern when caring for critically-ill patients who are mostly at risk of extensively drug-resistant Acinetobacter baumannii (XDRAB) infections. Hence even a single blood culture yielding XDRAB will tend to prompt intervention. However, field observations suggest that patients with single-positive blood cultures had milder disease and were more likely to be recruited in interventional studies than those with multiple-positive blood cultures, yet no distinction is made in current clinical or trial recruitment practices. To our knowledge, this is the first study to compare the clinical characteristics and outcomes of patients with single-positive versus multiple-positive blood cultures for XDRAB. In this multicenter prospective cohort study of XDRAB bacteremic patients from July 2010 to June 2015, only patients with at least two simultaneously drawn blood cultures were included. The patients were classified as having single-positive or multiple-positive blood cultures according to the number of positive blood cultures yielding XDRAB. The primary end-point was the 28-day mortality. Of a total of 155 patients enrolled, 69 had a single-positive and 86 had multiple-positive blood cultures. Leukopenia (37.2% vs. 16.2%; P = 0.004), thrombocytopenia (56.0% vs. 26.5%; P < 0.001), higher Pitt bacteremia scores (6.6 vs. 5.5, P = 0.03) and higher 28-day mortality rates (70.9% vs. 43.5%; P = 0.001) distinguished patients with multiple-positive from those with single-positive cultures. Multivariate logistic regression showed that multi-positivity independently predicted 28-day mortality (adjusted odds ratio, 2.34; 95% confidence interval (CI), 1.03-5.28; P = 0.04) and the Cox regression confirmed that multi-positivity (adjusted hazard ratio, 1.80; 95% CI, 1.13-2.85; P = 0.01) predicted rapid mortality. Patients with multiple versus single positive blood cultures yielding XDRAB had greater morbidity and mortality. Investigators and clinicians should be aware that the blood culture positivity rate impacts outcomes of XDRAB bacteremia.
[Mh] Termos MeSH primário: Infecções por Acinetobacter/diagnóstico
Bacteriemia/diagnóstico
Hemocultura/métodos
Farmacorresistência Bacteriana Múltipla
Leucopenia/diagnóstico
Trombocitopenia/diagnóstico
[Mh] Termos MeSH secundário: Infecções por Acinetobacter/tratamento farmacológico
Infecções por Acinetobacter/mortalidade
Infecções por Acinetobacter/patologia
Acinetobacter baumannii/efeitos dos fármacos
Acinetobacter baumannii/crescimento & desenvolvimento
Acinetobacter baumannii/patogenicidade
Idoso
Idoso de 80 Anos ou mais
Antibacterianos/farmacologia
Bacteriemia/tratamento farmacológico
Bacteriemia/mortalidade
Bacteriemia/patologia
Carbapenêmicos/farmacologia
Colistina/farmacologia
Estado Terminal
Feminino
Seres Humanos
Unidades de Terapia Intensiva
Leucopenia/tratamento farmacológico
Leucopenia/mortalidade
Leucopenia/patologia
Testes de Sensibilidade Microbiana
Meia-Idade
Estudos Prospectivos
Índice de Gravidade de Doença
Análise de Sobrevida
Trombocitopenia/tratamento farmacológico
Trombocitopenia/mortalidade
Trombocitopenia/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Carbapenems); Z67X93HJG1 (Colistin)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170922
[Lr] Data última revisão:
170922
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170708
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0180967


  8 / 2781 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28671537
[Au] Autor:Manohar P; Shanthini T; Ayyanar R; Bozdogan B; Wilson A; Tamhankar AJ; Nachimuthu R; Lopes BS
[Ad] Endereço:1​Department of Biomedical Sciences, School of Biosciences and Technology, Antibiotic Resistance Laboratory, VIT University, Vellore 632014, Tamil Nadu, India.
[Ti] Título:The distribution of carbapenem- and colistin-resistance in Gram-negative bacteria from the Tamil Nadu region in India.
[So] Source:J Med Microbiol;66(7):874-883, 2017 Jul.
[Is] ISSN:1473-5644
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:PURPOSE: The occurrence of carbapenem- and colistin-resistance among Gram-negative bacteria is increasing worldwide. The aim of this study was to understand the distribution of carbapenem- and colistin-resistance in two areas in Tamil Nadu, India. METHODOLOGY: The clinical isolates (n=89) used in this study were collected from two diagnostic centres in Tamil Nadu, India. The bacterial isolates were screened for meropenem- and colistin-resistance. Further, resistance genes blaNDM-1, blaOXA-48-like, blaIMP, blaVIM, blaKPC, mcr-1 and mcr-2 and integrons were studied. The synergistic effect of meropenem in combination with colistin was assessed. RESULTS: A total of 89 bacterial isolates were studied which included Escherichia coli (n=43), Klebsiella pneumoniae (n=18), Pseudomonas aeruginosa (n=10), Enterobacter cloacae (n=6), Acinetobacter baumannii (n=5), Klebsiella oxytoca (n=4), Proteus mirabilis (n=2) and Salmonella paratyphi (n=1). MIC testing showed that 58/89 (65 %) and 29/89 (32 %) isolates were resistant to meropenem and colistin, respectively, whereas 27/89 (30 %) isolates were resistant to both antibiotics. Escherichia coli, K. pneumoniae, K. oxytoca, Pseudomonas aeruginosa, and Enterobacter cloacae isolates were blaNDM-1-positive (n=20). Some strains of Escherichia coli, K. pneumoniae and K. oxytoca were blaOXA-181-positive (n=4). Class 1, 2 and 3 integrons were found in 24, 20 and 3 isolates, respectively. Nine NDM-1-positive Escherichia coli strains could transfer carbapenem resistance via plasmids to susceptible Escherichia coli AB1157. Meropenem and colistin showed synergy in 10/20 (50 %) isolates by 24 h time-kill studies. CONCLUSION: Our results highlight the distribution of carbapenem- and colistin-resistance in Gram-negative bacteria isolated from the Tamil Nadu region in South India.
[Mh] Termos MeSH primário: Antibacterianos/farmacologia
Colistina/farmacologia
Farmacorresistência Bacteriana
Bactérias Gram-Negativas/efeitos dos fármacos
Infecções por Bactérias Gram-Negativas/microbiologia
Tienamicinas/farmacologia
[Mh] Termos MeSH secundário: Sinergismo Farmacológico
Genes Bacterianos
Bactérias Gram-Negativas/isolamento & purificação
Seres Humanos
Índia
Testes de Sensibilidade Microbiana
Reação em Cadeia da Polimerase
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Thienamycins); FV9J3JU8B1 (meropenem); Z67X93HJG1 (Colistin)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170809
[Lr] Data última revisão:
170809
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170704
[St] Status:MEDLINE
[do] DOI:10.1099/jmm.0.000508


  9 / 2781 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28657722
[Au] Autor:Zhu C; Schneider EK; Nikolaou V; Klein T; Li J; Davis TP; Whittaker MR; Wilson P; Kempe K; Velkov T; Haddleton DM
[Ad] Endereço:Department of Chemistry, University of Warwick , Coventry CV4 7AL, United Kingdom.
[Ti] Título:Hydrolyzable Poly[Poly(Ethylene Glycol) Methyl Ether Acrylate]-Colistin Prodrugs through Copper-Mediated Photoinduced Living Radical Polymerization.
[So] Source:Bioconjug Chem;28(7):1916-1924, 2017 Jul 19.
[Is] ISSN:1520-4812
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Through the recently developed copper-mediated photoinduced living radical polymerization (CP-LRP), a novel and well-defined polymeric prodrug of the antimicrobial lipopeptide colistin has been developed. A colistin initiator (Boc -col-Br ) was synthesized through the modification of colistin on both of its threonine residues using a cleavable initiator linker, 2-(2-bromo-2-methylpropanoyloxy) acetic acid (BMPAA), and used for the polymerization of acrylates via CP-LRP. Polymerization proceeds from both sites of the colistin initiator, and through the polymerization of poly(ethylene glycol) methyl ether acrylate (PEGA ), three water-soluble polymer-colistin conjugates (col-PPEGA, having degrees of polymerization of 5, 10, and 20) were achieved with high yield (conversion of ≥93%) and narrow dispersities (D < 1.3) in 2-4 h. Little or no effect on the structure and activity of the colistin was observed during the synthesis, and most of the active colistin can be recovered from the conjugates in vitro within 2 days. Furthermore, in vitro biological analyses including disk diffusion, broth microdilution, and time-kill studies suggested that all of the conjugates have the ability to inhibit the growth of multidrug-resistant (MDR) Gram-negative bacteria, of which col-PPEGA DP5 and DP10 showed similar or better antibacterial performance compared to the clinically relevant colistin prodrug CMS, indicating their potential as an alternative antimicrobial therapy. Moreover, considering the control over the polymerization, the CP-LRP technique has the potential to provide an alternative platform for the development of polymer bioconjugates.
[Mh] Termos MeSH primário: Acrilatos/química
Colistina/química
Polietilenoglicóis/química
Polimerização/efeitos da radiação
Pró-Fármacos/síntese química
[Mh] Termos MeSH secundário: Antibacterianos/síntese química
Cobre/química
Resistência a Múltiplos Medicamentos/efeitos dos fármacos
Bactérias Gram-Negativas/efeitos dos fármacos
Hidrólise
Processos Fotoquímicos
Relação Estrutura-Atividade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Acrylates); 0 (Anti-Bacterial Agents); 0 (Prodrugs); 30IQX730WE (Polyethylene Glycols); 789U1901C5 (Copper); WC487PR91H (methyl acrylate); Z67X93HJG1 (Colistin)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170817
[Lr] Data última revisão:
170817
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170629
[St] Status:MEDLINE
[do] DOI:10.1021/acs.bioconjchem.7b00242


  10 / 2781 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28652741
[Au] Autor:Sans-Serramitjana E; Jorba M; Pedraz JL; Vinuesa T; Viñas M
[Ad] Endereço:Laboratory of Molecular Microbiology and Antimicrobials, Department of Pathology and Experimental Therapeutics, University of Barcelona, Barcelona.
[Ti] Título:Determination of the spatiotemporal dependence of biofilm viability after treatment with NLC-colistin.
[So] Source:Int J Nanomedicine;12:4409-4413, 2017.
[Is] ISSN:1178-2013
[Cp] País de publicação:New Zealand
[La] Idioma:eng
[Ab] Resumo:The emergence of colistin-resistant in cystic fibrosis (CF) patients, particularly after long-term inhalation treatments, has been recently reported. Nanoen-capsulation may enable preparations to overcome the limitations of conventional pharmaceutical forms. We have determined the time-dependent viability of biofilms treated with both free and nanoencapsulated colistin. We also examined the relationship between the optimal anti-biofilm activity of nanostructured lipid carrier (NLC)-colistin and the structural organization of the biofilm itself. The results showed the more rapid killing of bacterial biofilms by NLC-colistin than by free colistin. However, the two formulations did not differ in terms of the final percentages of living and dead cells, which were higher in the inner than in the outer layers of the treated biofilms. The effective anti-biofilm activity of NLC-colistin and its faster killing effect recommend further studies of its use over free colistin in the treatment of infections in CF patients.
[Mh] Termos MeSH primário: Antibacterianos/farmacologia
Colistina/farmacologia
Portadores de Fármacos/farmacologia
Pseudomonas aeruginosa/efeitos dos fármacos
[Mh] Termos MeSH secundário: Antibacterianos/administração & dosagem
Antibacterianos/química
Biofilmes/efeitos dos fármacos
Colistina/administração & dosagem
Colistina/química
Fibrose Cística/microbiologia
Portadores de Fármacos/administração & dosagem
Portadores de Fármacos/química
Seres Humanos
Lipídeos/administração & dosagem
Lipídeos/química
Testes de Sensibilidade Microbiana
Nanoestruturas
Análise Espaço-Temporal
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Drug Carriers); 0 (Lipids); Z67X93HJG1 (Colistin)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171002
[Lr] Data última revisão:
171002
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170628
[St] Status:MEDLINE
[do] DOI:10.2147/IJN.S138763



página 1 de 279 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde